Considering that the patient’s tumor was mainly composed of MTC, it is recommended that the patient undergo RET and BRAF gene somatic testing to evaluate the prognosis and provide a basis for targeted therapy. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.